Tongli Pharmaceuticals (USA), Inc. (TGLP) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
125 MAIDEN LANE, SUITE 309 NEW YORK, NY 10038 |
| State of Incorp. | DE |
| Fiscal Year End | March 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2013 | |||
|---|---|---|---|
| ASSETS | |||
| Current Assets | |||
| Cash, cash equivalents, and short-term investments | |||
| Cash and cash equivalent | |||
| Receivables | |||
| Inventory, net of allowances, customer advances and progress billings | |||
| Inventory | |||
| Advances on inventory purchases | |||
| Prepaid expense and other current assets | |||
| Other undisclosed current assets | |||
| Total current assets: | |||
| Noncurrent Assets | |||
| Property, plant and equipment | |||
| Intangible assets, net (including goodwill) | |||
| Intangible assets, net (excluding goodwill) | |||
| Deposits noncurrent assets | |||
| Total noncurrent assets: | |||
| TOTAL ASSETS: | |||
| LIABILITIES AND EQUITY | |||
| Liabilities | |||
| Current Liabilities | |||
| Accounts payable and accrued liabilities | |||
| Taxes payable | |||
| Accounts payable | |||
| Accrued liabilities | |||
| Due to related parties | |||
| Total current liabilities: | |||
| Noncurrent Liabilities | |||
| Total liabilities: | |||
| Equity | |||
| Equity, attributable to parent | |||
| Common stock | |||
| Additional paid in capital | |||
| Accumulated other comprehensive income | |||
| Retained earnings | |||
| Total equity: | |||
| TOTAL LIABILITIES AND EQUITY: | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2013 | ||
|---|---|---|
| Revenues (Revenue, Net) | ||
| Cost of revenue (Cost of Product and Service Sold) | ||
| Other undisclosed gross profit | ||
| Gross profit: | ||
| Operating expenses | ||
| Operating income: | ||
| Nonoperating expense | ||
| Investment income, nonoperating | ||
| Other nonoperating income | ||
| Interest and debt expense | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | ||
| Income from continuing operations before income taxes: | ||
| Income tax expense | ||
| Income from continuing operations: | ||
| Income before gain (loss) on sale of properties: | ||
| Net income available to common stockholders, diluted: | ||
Comprehensive Income ($ in thousands)
| 3/31/2013 | ||
|---|---|---|
| Net income: | ||
| Comprehensive income: | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | ||
| Comprehensive income, net of tax, attributable to parent: | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.